Ann: Results of Meeting, page-12

I dont think thorneys options had anything to do with the price dropping from 10c.

it was a pump and dump period.

criticising how management rolled out both launches late with no supporting coms other than an asx anns really only exaggerated the short lived pump and pace of a retrace.

zelira clearly isnt focused on leveraging its deliverables and appears integrisly committed to jusr doing what it said it would do. Which is build a portfolio of world first drugs.
Clinically validated as safe effective treatmens.
Positioned in a once in a generation emerging new market.
Generating revenues globally through robust commercial models that include licencing agreement strategies across the universe of united states. And then traditional manufacturing and distribution models across the rest of the world starting with australia.

The work with autism and insomnia to name two ... suggest huge potential.

Zelira know this and are committed to this strategy.

Problem is.... you are years away from said business unlocking, legitimate, value with staying power. Its a biotech pump and dump.

Treat it as such.

Expecting some random thing in the near term to rerate this is delusional.

It may or may not happen. Could get a right pump that sees this at 15c in december?
Who knows. Totally possible.

What im saying is that then your investment expectation and strategy is nothing more than a punt.

If one holds a near term view with this that is.

Good luck.